Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298399 | 0.82 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL4298394 | 0.82 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL1914725 | 0.79 | MEN1 (0.44) | LMNA | |
| SCHEMBL17242704 | 0.77 | CRHBP (0.48) | TAS1R3TAS1R1LMNARAB9A | |
| SCHEMBL18975197 | 0.73 | TUBB1 (0.56) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL30690418 | 0.72 | GAA (0.47) | SMN1; SMN2MAPK1HTT | |
| SCHEMBL16307888 | 0.71 | MAPT (0.57) | LMNAMAPK1HTT | |
| SCHEMBL6132092 | 0.71 | GAA (0.55) | SMN1; SMN2MAPK1HTTRAB9A | |
| SCHEMBL6132093 | 0.71 | GAA (0.55) | SMN1; SMN2MAPK1HTTRAB9A | |
| SCHEMBL15668950 | 0.70 | TUBB1 (0.60) | TUBB1LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | TUBB1 92/4885SMN1; SMN2 2808/4885TAS1R3 2337/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | TUBB1 257/4885SMN1; SMN2 3662/4885TAS1R3 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.